138 related articles for article (PubMed ID: 18636761)
1. The binding orientation of a norindenoisoquinoline in the topoisomerase I-DNA cleavage complex is primarily governed by pi-pi stacking interactions.
Song Y; Cushman M
J Phys Chem B; 2008 Aug; 112(31):9484-9. PubMed ID: 18636761
[TBL] [Abstract][Full Text] [Related]
2. On the binding of indeno[1,2-c]isoquinolines in the DNA-topoisomerase I cleavage complex.
Xiao X; Antony S; Pommier Y; Cushman M
J Med Chem; 2005 May; 48(9):3231-8. PubMed ID: 15857129
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis.
Ioanoviciu A; Antony S; Pommier Y; Staker BL; Stewart L; Cushman M
J Med Chem; 2005 Jul; 48(15):4803-14. PubMed ID: 16033260
[TBL] [Abstract][Full Text] [Related]
4. A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex.
Marchand C; Antony S; Kohn KW; Cushman M; Ioanoviciu A; Staker BL; Burgin AB; Stewart L; Pommier Y
Mol Cancer Ther; 2006 Feb; 5(2):287-95. PubMed ID: 16505102
[TBL] [Abstract][Full Text] [Related]
5. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex.
Staker BL; Feese MD; Cushman M; Pommier Y; Zembower D; Stewart L; Burgin AB
J Med Chem; 2005 Apr; 48(7):2336-45. PubMed ID: 15801827
[TBL] [Abstract][Full Text] [Related]
6. Nitrated indenoisoquinolines as topoisomerase I inhibitors: a systematic study and optimization.
Morrell A; Placzek M; Parmley S; Antony S; Dexheimer TS; Pommier Y; Cushman M
J Med Chem; 2007 Sep; 50(18):4419-30. PubMed ID: 17696418
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and anticancer activity of simplified indenoisoquinoline topoisomerase I inhibitors lacking substituents on the aromatic rings.
Nagarajan M; Morrell A; Fort BC; Meckley MR; Antony S; Kohlhagen G; Pommier Y; Cushman M
J Med Chem; 2004 Nov; 47(23):5651-61. PubMed ID: 15509164
[TBL] [Abstract][Full Text] [Related]
8. 7-azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents.
Kiselev E; DeGuire S; Morrell A; Agama K; Dexheimer TS; Pommier Y; Cushman M
J Med Chem; 2011 Sep; 54(17):6106-16. PubMed ID: 21823606
[TBL] [Abstract][Full Text] [Related]
9. An ab initio quantum mechanics calculation that correlates with ligand orientation and DNA cleavage site selectivity in camptothecin-DNA-topoisomerase I ternary cleavage complexes.
Xiao X; Cushman M
J Am Chem Soc; 2005 Jul; 127(28):9960-1. PubMed ID: 16011334
[TBL] [Abstract][Full Text] [Related]
10. Azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents: a systematic study of structure-activity relationships.
Kiselev E; Agama K; Pommier Y; Cushman M
J Med Chem; 2012 Feb; 55(4):1682-97. PubMed ID: 22329436
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of new indeno[1,2-c]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors.
Cushman M; Jayaraman M; Vroman JA; Fukunaga AK; Fox BM; Kohlhagen G; Strumberg D; Pommier Y
J Med Chem; 2000 Oct; 43(20):3688-98. PubMed ID: 11020283
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of new fluorinated and chlorinated indenoisoquinoline topoisomerase I poisons.
Beck DE; Lv W; Abdelmalak M; Plescia CB; Agama K; Marchand C; Pommier Y; Cushman M
Bioorg Med Chem; 2016 Apr; 24(7):1469-79. PubMed ID: 26906474
[TBL] [Abstract][Full Text] [Related]
13. The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.
Pommier Y; Cushman M
Mol Cancer Ther; 2009 May; 8(5):1008-14. PubMed ID: 19383846
[TBL] [Abstract][Full Text] [Related]
14. Discovery of potent indenoisoquinoline topoisomerase I poisons lacking the 3-nitro toxicophore.
Beck DE; Abdelmalak M; Lv W; Reddy PV; Tender GS; O'Neill E; Agama K; Marchand C; Pommier Y; Cushman M
J Med Chem; 2015 May; 58(9):3997-4015. PubMed ID: 25909279
[TBL] [Abstract][Full Text] [Related]
15. Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints.
Pommier Y
Curr Med Chem Anticancer Agents; 2004 Sep; 4(5):429-34. PubMed ID: 15379698
[TBL] [Abstract][Full Text] [Related]
16. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.
Antony S; Jayaraman M; Laco G; Kohlhagen G; Kohn KW; Cushman M; Pommier Y
Cancer Res; 2003 Nov; 63(21):7428-35. PubMed ID: 14612542
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design, synthesis, and biological studies of new anticancer norindenoisoquinoline topoisomerase I inhibitors.
Song Y; Shao Z; Dexheimer TS; Scher ES; Pommier Y; Cushman M
J Med Chem; 2010 Mar; 53(5):1979-89. PubMed ID: 20155916
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of indenoisoquinoline topoisomerase I inhibitors featuring polyamine side chains on the lactam nitrogen.
Nagarajan M; Xiao X; Antony S; Kohlhagen G; Pommier Y; Cushman M
J Med Chem; 2003 Dec; 46(26):5712-24. PubMed ID: 14667224
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of nitrated 7-, 8-, 9-, and 10-hydroxyindenoisoquinolines as potential dual topoisomerase I (Top1)-tyrosyl-DNA phosphodiesterase I (TDP1) inhibitors.
Nguyen TX; Abdelmalak M; Marchand C; Agama K; Pommier Y; Cushman M
J Med Chem; 2015 Apr; 58(7):3188-208. PubMed ID: 25811317
[TBL] [Abstract][Full Text] [Related]
20. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
Fan Y; Weinstein JN; Kohn KW; Shi LM; Pommier Y
J Med Chem; 1998 Jun; 41(13):2216-26. PubMed ID: 9632354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
